Rehmann Capital Advisory Group’s Editas Medicine EDIT Stock Holding History

Rehmann Capital Advisory Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$3.21K	Hold	141	–	–	﹤0.01%	1318
2019 Q2	$3.49K	Hold	141	–	–	﹤0.01%	1643
2019 Q1	$3.45K	Hold	141	–	–	﹤0.01%	1621
2018 Q4	$3.21K	Sell	141 -159	-53%	-$4.33K	﹤0.01%	1351
2018 Q3	$9.55K	Hold	300	–	–	﹤0.01%	1377
2018 Q2	$10.7K	Sell	300 -4,633	-94%	-$164K	﹤0.01%	1318
2018 Q1	$164K	Buy	+4,933	New	+$176K	0.03%	425

Other funds holding EDIT

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rehmann Capital Advisory Group's EDIT Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Editas Medicine (EDIT) position steady in Q3 2019 at 141 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Rehmann Capital Advisory Group first reported a position in EDIT in Q1 2018 and has held it in 7 quarters since. The position peaked at $164K in Q1 2018. 187 funds tracked by Wall St. Rank hold EDIT as of Q3 2019.

Rehmann Capital Advisory Group held 141 shares of Editas Medicine worth $3.21K as of Q3 2019.
Rehmann Capital Advisory Group left its Editas Medicine share count unchanged in Q3 2019.
Editas Medicine made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1318 holding.
Rehmann Capital Advisory Group first reported a position in Editas Medicine in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Editas Medicine position peaked at $164K in Q1 2018.
187 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.